

Allmpus expedites OTC healthcare products in post-COVID world

29 July 2020 | News | By Pooja Yadav

The move will steer the enterprise into the new market, fulfilling the rising demand for OTC products amongst Indian consumers



Mumbai based Allmpus Laboratories, one of India's leading research-based pharmaceutical enterprises, eyes to enter the OTC market in the post-COVID world. The move will steer the enterprise into the new market, fulfilling the rising demand for OTC products amongst Indian consumers.

The OTC drug market in India stood at \$6.38 billion in 2019, with an estimated CAGR of 19.4%. By 2024 the market is expected to reach 15.48 billion. With the sentiment of self-sufficiency running strong in the country and anticipated positive growth may happen sooner than expected.

Factors like unhealthy dietary habits, lifestyle diseases, rising fear of COVID-19, and the unavoidable need to build immunity have contributed to the spiraling demand for OTC products in India.

Moreover, behavioral changes in society with more health-conscious consumers and their changing attitudes towards self-medication also act as catalysts in the increasing demand. India pharmaceutical companies are inclining towards OTC drug production in the coming future.

Allmpus Laboratories carry out extensive R & D to come up with new medical essential products while mustering production strength to make them available on a large scale during the post-pandemic time.